The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research.
The Journal of Clinical Oncology (JCO) serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.
JCO's Impact Factor is 24.008 as reported by Clarivate in its 2016 Journal Citation Reports (last updated June 2017). The publication is indexed in the following services: Abstracts of Health Care Management Studies, Automatic Subject Citation Index, Chemical Abstracts, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Current Contents (Clinical Medicine, ISI/BioMed, Life Sciences, Science Citation Index, SCISEARCH), EMBASE/Excerpta Medica, Index Medicus/MEDLINE, Neuroscience Citation Index, and EBSCOHOST Electronic Journals Service.
JCO is published by the American Society of Clinical Oncology. Harborside serves as the advertising sales representative for this publication.
Stephen A. Cannistra, MD
Since 1989, Dr. Cannistra has been working to make the Journal of Clinical Oncology the most credible, authoritative resource for disseminating significant clinical oncology research while acting as a reviewer, Consultant Editor, Associate Editor, Editorial Board Member, and as of 2011, Editor-in-Chief.
Dr. Cannistra is Professor of Medicine at Harvard Medical School; Attending Physician on the Medical Oncology Service at Dana-Farber Cancer Institute; and Director of Gynecologic Medical Oncology at Beth Israel Deaconess Medical Center.View Editorial Board
The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. JCO has more than 35,000 subscribers, including ASCO members and other physicians and researchers worldwide, as well as more than 7,500 institutional subscribers.
Advertising opportunities exist in print, the website, for electronic table of contents and targeted malignancy emails, and more. Further details are available in the media kit and rate card. Please contact our advertising representatives with any inquiries. All advertisements are subject to ASCO's Advertising Policy.
National Accounts Representative, ASCO Publications
VP, Director of Advertising Sales, The ASCO Post
VP, Senior Accounts Manager, ASCO Publications